“Intermediate results of the prospective randomized controlled trial VOG-01: ‘Evaluation of the efficacy of neoadjuvant combination hormone therapy in premenopausal patients with ER+ HER2- breast cancer’”., Вопр. онкол., vol. 68, no. 3, pp. 354–361, Jul. 2022, doi: 10.37469/0507-3758-2022-68-3-354-361.